NIH

The idea Karl Zelik (Vanderbilt University) Erik Lamers (Vanderbilt University) Karl E. Zelik, assistant professor of mechanical engineering, and recent Ph.D. graduate Erik P. Lamers revealed a new exosuit designed to bring back relief to workers who have been under high strain throughout the pandemic, including last-mile delivery drivers and essential workers. The suit can... Read More

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets. Read More

Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people. Read More

High-intensity strength training is not more effective than low-intensity training or educational efforts for reducing knee pain in patients with osteoarthritis. Read More

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes. Read More

Since the inception of the Vanderbilt I-Corps Site Program just three years ago, more than 20 teams of VU innovators have been accepted into the National Science Foundation’s prestigious National I-Corps Program, turning their STEM ideas and research into novel inventions that improve health care, strengthen cybersecurity, produce clean energy, support people battling drug abuse and mental health disorders and more. Read More

A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease. Read More

Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy. Read More

Vanderbilt researchers have linked bone-related complications of severely injured patients — findings that could help minimize these complications. Read More

The National Institutes of Health has now posted information for the 2021 S10 Shared and High-end Instrumentation Grants programs. Both programs have an NIH submission deadline of June 1, 2021. Read More

Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study. Read More

A Vanderbilt research team has received a $2 million National Institutes of Health grant to further develop a needle-size robotic surgery system with real-time MRI guidance for drug resistant temporal lobe epilepsy (TLE). Such a procedure has the potential to reduce or eliminate seizures using a minimally invasive approach over the current standard of care,... Read More

A noninvasive, quantitative MRI method could be used after surgical repair of traumatic peripheral nerve injury to help clinicians make decisions about whether additional surgical interventions are needed. Read More

HIV-1, the virus that causes AIDS, exploits inositol phosphates in T cells to aid its own assembly and maturation — suggesting that targeting inositol phosphate binding could inhibit HIV-1 replication. Read More

Insight into the pathophysiology of an enigmatic and debilitating disease suggests new treatment approaches. Read More

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment. Read More

Researchers will combine expertise in developmental cell biology and tissue engineering/microfluidics to develop highly complex organoids, with the goal of understanding currently incurable neurological disorders.  Read More

A blood stem cell protein plays a role in the initiation and progression of leukemia, Vanderbilt researchers have found. Read More

Brain inflammation links genetic and acquired epilepsy — providing new clues about epilepsy development and pointing to potential treatments. Read More

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth. Read More